RAP-RL
| 【Numbering】BKME108001 | 【CAS】CAS | ||
| 【Item No.】BKME108001-2 | 【specification】 | ||
|
|||
Name: RAP-RL
Composition: Glycation end product (RAGE) receptor antagonist peptide + monosialate tetrahexosyl ganglioside + apolipoprotein E3 particle size: 10-50nm
Application: anti-tumor
Storage conditions: -4℃
Other instructions: sealed shelf life [main advantages] RAP-RL through RAP and RAGE specific binding accumulation in the cerebral microvessels, effectively accelerate the clearance of perivascular A β, normalize the cerebrovascular morphology and function, restore the structural integrity and function of NVU, and can significantly improve the spatial learning and memory ability of APP / PS1 mice.
Message
Composition: Glycation end product (RAGE) receptor antagonist peptide + monosialate tetrahexosyl ganglioside + apolipoprotein E3 particle size: 10-50nm
Application: anti-tumor
Storage conditions: -4℃
Other instructions: sealed shelf life [main advantages] RAP-RL through RAP and RAGE specific binding accumulation in the cerebral microvessels, effectively accelerate the clearance of perivascular A β, normalize the cerebrovascular morphology and function, restore the structural integrity and function of NVU, and can significantly improve the spatial learning and memory ability of APP / PS1 mice.
Title:Multifunctional Nanostructure RAP-RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit
Article link:DOI: 10.1002/advs.202001918| Warm tips: Suzhou Beike nano products are only used for scientific research, not for human body,different batches of products have different specifications and performance |
Message
|
| Warm tips: Suzhou Beike nano products are only used for scientific research, not for human body,different batches of products have different specifications and performance.The website pictures are from the Internet. The pictures are for reference only. Please take the real object as the standard. In case of infringement, please contact us to delete them immediately. |
Previous： the end...
Next： DIRAs
